Jimini raises $17M seed for clinician-supervised AI therapy
Key Questions
What is Jimini Health's recent funding achievement?
Jimini Health closed a $17M seed round, bringing total funding to over $25M, led by M13 and Zetta. The funding supports their clinician-supervised Sage AI platform for behavioral health.
What are the key features of Jimini Health's Sage AI platform?
The platform ensures CMS and FDA compliance and has been tested in their own clinic. It is backed by founders from Immunai and Guardant, with advisors from Harvard, Yale, and Moderna.
What diligence points and risks are associated with Jimini Health?
Key diligence areas include large organization and payor partnerships, proof of outcomes, and responsible scaling. It reinforces the agentic health surge amid regulatory and failure risks, similar to companies like Blossom, Mantis, and Acurion.
Jimini Health closed $17M seed (total $25M+, M13/Zetta-led) for clinician-supervised Sage AI platform in behavioral health, with CMS/FDA compliance, Immunai/Guardant founders, Harvard/Yale/Moderna advisors, and own clinic testing. Reinforces agentic health surge (Blossom/Mantis/myStoria/Health Universe/Rivia/RyboDyn/Acurion) amid regulatory/failure risks. Diligence: large org/payor partnerships, outcomes proof, responsible scaling.